Esther Liu Mondo, MD

Description

My approach to medicine is team based and patient centered. We have a multidisciplinary approach to treating cancer and involve a very cohesive team to help patients and their families. I pride myself on making sure patients and their friends and families understand all the diagnostic and treatment options available to them, as well as the potential benefits and risks of treatment, in order for patients to make educated decisions about their care. I educate so that patients and their families comprehend fully the details of their diagnosis, the work up, the treatment decision making process, and results of their studies. I want to ensure that my patient's treatment is consistent with the most updated national guidelines and evidence based medicine.

Keywords human epidural growth factor 2 mutation, microsatellite stability, minimal residual disease, bone marrow stimulation, clonal cytopenia of undetermined significance, immune therapy, cancer risk, hydroxyurea therapy, squamous cell carcinoma, thalassemia trait, hemophilia carrier, acquired factor inhibitor, histiocytoma, systemic mastocytosis, aranesp injection, octreotide treatment, lacrimal gland cancer, nucleated red blood cell count, giant platelet syndrome, electrolyte abnormalities in cancer patients, malignant spindle cell neoplasm, small intestine cancer chemotherapy, small cell lung cancer chemotherapy, biliary tract cancer chemotherapy, gallbladder cancer chemotherapy, tongue cancer chemotherapy, laryngeal cancer chemotherapy, head and neck cancer chemotherapy, tracheal cancer chemotherapy, hypopharyngeal cancer chemotherapy, anal cancer chemotherapy, nasopharyngeal cancer chemotherapy, esophageal cancer chemotherapy, brain cancer chemotherapy, eye cancer chemotherapy, appendiceal cancer chemotherapy, eyelid cancer chemotherapy, colorectal cancer chemotherapy, throat cancer chemotherapy, spleen cancer chemotherapy, anorectal cancer chemotherapy, penile cancer chemotherapy, pancreatic cancer chemotherapy, liver cancer chemotherapy, mouth cancer chemotherapy, stomach cancer chemotherapy, pleural cancer chemotherapy, adjuvant chemotherapy, t-cell prolymphocytic leukemia, neutrophilia, monoclonal b-cell lymphocytosis, follicular t-cell lymphoma, elevated transferrin saturation, elevated ferritin, high iron, large cell neuroendocrine tumors, autoimmune (aa) amyloidosis, light chain (al) amyloidosis, solid tumors, metastatic blood cancers, cancer of the muscles, cancer of the joints, advanced malignancies, systemic therapy, familial amyloidosis, androgen deprivation therapy, liquid biopsy testing, gleason score, renal cell carcinoma immunotherapy, squamous cell carcinoma of penis, human papillomavirus (hpv) related penile cancer, skin cancer on penis, hereditary papillary renal cell cancer, familial renal cell carcinoma, hereditary kidney cancer, renal sarcoma, renal pelvis carcinoma, muscle invasive bladder cancer, adenocarcinoma of the bladder, squamous cell carcinoma of bladder, spherocytosis, nut carcinoma, personal history of cancer, intestinal cancer, relapsed acute myelogenous leukemia (aml), bleeding disorder clinics, malignant lung tumors, skin cancer of the face, breast cancer biological targeted therapy, metastatic rib cancer, t cell acute lymphoblastic leukemia, relapsed non hodgkin lymphoma, relapsed hodgkin lymphoma, relapsed acute lymphoblastic leukemia (all), lymphoproliferative disorder, hereditary retinoblastoma, autoimmune lymphoproliferative syndrome (alps), alk negative anaplastic large cell lymphoma, smoldering multiple myeloma, autoimmune cytopenia.